SCHEMBL3151371

SCHEMBL3151371

NC(=O)OC1CCCNC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP2D6 P10635 1/20 0.52
SLC6A1 P30531 2/20 0.44
SLC6A11 P48066 1/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLC6A13 Q9NSD5 1/20 0.44
APLNR P35414 2/20 0.42
NOS2 P35228 1/20 0.42
IRAK4 Q9NWZ3 2/20 0.38
CHEK2 O96017 1/20 0.36
CPN1 P15169 1/20 0.35
CPB2 Q96IY4 1/20 0.35
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
GLI1 P08151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3151408 1.00 ATM (0.52) ATMKDM4EMAPTKMT2ACYP2D6
SCHEMBL3151369 1.00 ATM (0.52) ATMKDM4EMAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL9836717 0.98 ATM (0.50) ATMKDM4EMAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL6496594 0.98 ATM (0.50) ATMKDM4EMAPTKMT2ACYP2D6
Hydrochloric Acid SCHEMBL6496588 0.98 ATM (0.50) ATMKDM4EMAPTKMT2ACYP2D6
SCHEMBL22829610 0.94 ATM (0.46) ATMKDM4EMAPTKMT2ACYP2D6
SCHEMBL22829611 0.94 ATM (0.46) ATMKDM4EMAPTKMT2ACYP2D6
SCHEMBL184224 0.88
SCHEMBL3155834 0.88
SCHEMBL3145317 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151501-A1 Compounds having growth hormone releasing activity BOWERS CYRIL Y (US) 2002-10-17 US claimed
EP-1159292-A2 COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY Administrators of The Tulane Educational Fund (US) 2001-12-05 EP claimed
WO-2000009537-A2 COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2000-02-24 WO claimed
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 WO disclosed
WO-2024107434-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2024-05-23 WO disclosed
CN-117794924-A Compounds useful as inhibitors of ATR kinase 苏州爱科百发生物医药技术有限公司 2024-03-29 CN disclosed
WO-2024022244-A1 HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY 首药控股(北京)股份有限公司 2024-02-01 WO disclosed
CN-117062813-A Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2023-11-14 CN disclosed
CN-116917279-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2023-10-20 CN disclosed
CN-111094265-B Pyrazole derivative compound and use thereof 韩美药品株式会社 2023-07-25 CN disclosed
WO-1994019352-A1 MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) 1994-09-01 WO disclosed
EP-0447013-B1 Fluorobenzene sulphonamides SCHERING AG (DE) 1994-08-03 EP disclosed
EP-0263059-B1 COMPLEXES AMIDES SCHERING AKTIENGESELLSCHAFT (DE) 1992-11-11 EP disclosed
EP-0447013-A1 Fluorobenzene sulphonamides SCHERING AKTIENGESELLSCHAFT (DE) 1991-09-18 EP disclosed
EP-0413405-A2 Use of amide complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1991-02-20 EP disclosed
EP-0336879-A1 Meso-tetraphenylporphyrin complex compounds,process for their preparation and pharmaceuticals containing them SCHERING AKTIENGESELLSCHAFT (DE) 1989-10-11 EP disclosed
EP-0263059-A2 Complexes amides SCHERING AKTIENGESELLSCHAFT (DE) 1988-04-06 EP disclosed
EP-0255471-A1 1,4,7,10-Tetraazacyclododecane-derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1988-02-03 EP disclosed
EP-0252876-A1 Hydrogenated 1-phenoxyalkylpyridine-3-carboxylic-acid compounds CIBA-GEIGY AG (CH) 1988-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151501-A1 Compounds having growth hormone releasing activity GHSR, GHRHR, NPY1R ATM 1833/4885KDM4E 3418/4885MAPT 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.